A plan by the National Institutes of Health to award an exclusive license for a CAR-T therapy that was funded by U.S. taxpayers to a group of biotech venture capitalists has sparked concerns among advocacy groups over pricing and access in the U.S. and elsewhere.

At issue are patent rights for an acute myeloid leukemia treatment the agency recently indicated would be awarded to an obscure company called ElevateBio, which was created by four current or former partners at MPM Capital. The venture capital firm has invested in dozens of companies, including 23andMe and Pharmasset, which is credited with discovering the breakthrough Sovaldi hepatitis C medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy